QuantideX®
qPCR DNA QC Assay

MEASURE THE DNA THAT MATTERS



QUANTIFY FUNCTIONAL DNA
Measure PCR-amplifiable DNA and discover PCR inhibition within the sample, guiding smarter sample input for NGS projects.

RESCUE LOW PERFORMING SAMPLES
Calculate sample input based on functional DNA template rather than bulk DNA, ensuring enough sample complexity to avoid false calls and expensive run failures.

SIMPLE WORKFLOW
Rapid, single-reaction qPCR-based assay that can be set up in less than 10 minutes.

CONVENIENT REPORTING
Leverage the easy-to-use QuantideX® qPCR DNA QC Assay* reporting tool to automatically calculate functional DNA copy number and minimum sample input requirements.

The QuantideX® qPCR DNA QC Assay* is a multiplexed quantitative PCR assay that measures the absolute copy number of PCR-amplifiable DNA in a sample and reports PCR inhibition.

The QuantideX® qPCR DNA QC Assay* determines the functional quality of sample DNA using the Quantitative Functional Index (QFI™) Score, designating the fraction of total genomic DNA copies that can be successfully amplified. The QFI™ Score and amplifiable copy number provide actionable guidance that informs the input requirements for NGS target enrichment and helps assure a high level of analytical sensitivity and specificity. In addition, the QuantideX® qPCR DNA QC Assay* flags PCR inhibitors in the sample and provides an opportunity to salvage such samples through a subsequent clean-up step prior to further processing.

Convenient Reporting

Asuragen® Oncology

*Research Use Only. Not for use in diagnostic procedures.

QuantideX®
qPCR DNA QC Assay

KIT ORDERING INFORMATION

QUANTIDEX® qPCR DNA QC ASSAY
[P/N 49539] 100 Reactions.

*Research Use Only. Not for use in diagnostic procedures.

REFERENCES

1. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Sah et al. Genome Med 2013;5(8):77
2. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. Choudhary et al. BMC Med Genomics 2014;(7):62
3. Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: A diagnostic RING trial. Kapp et al. J Clin Pathol 2015;(68):111-118

WATCH THE TECH TALK

"Measure the DNA that Matters: The QuantideX® DNA Assay as the Foundation for an Integrated NGS Workflow Solution"

Presented by: Sachin Sah, M.S., PMP
www.asuragen.com/tech-talks

Vertrieb durch:

VIROTECH Diagnostics GmbH
Löwenplatz 5
D-65428 Rüsselsheim
+49 (0)6142 69090

Asuragen®
Oncology

Asuragen, Inc.
2150 Woodward Street, Suite 100
Austin TX 78744
asuragen.com

2500-0537